- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07938814
A Phase I/II, Dose-Escalation and Dose-Expansion Study of CS5006, in Participants With Advanced Solid Tumors
A Phase I/II, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activities of CS5006, a Novel Antibody-Drug Conjugate Targeting ITGB4, in Participants With Advanced Solid Tumors
This is a first-in-human (FIH), open-label, and multi-center Phase I/II study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of CS5006 in participants with advanced solid tumors. The study comprises of a Phase I dose escalation and Phase II dose expansion.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
In Phase I, participants with specified advanced epithelial solid tumors will be enrolled to establish the MTD, if any, and tentative RP2D(s) of CS5006. The specified advanced epithelial solid tumors included but not limited non-small cell lung cancer (NSCLC), colorectal cancer (CRC), squamous cell carcinoma of head and neck (HNSCC), urothelial carcinoma (UC), triple-negative breast cancer (TNBC), cervical cancer (CC), esophageal squamous cell carcinoma (ESCC) , endometrial cancer, ovarian cancer (OC), renal cell carcinoma (RCC), small cell lung cancer (SCLC), hepatocellular carcinoma (HCC), biliary tract cancer (BTC), gastric cancer (GC), pancreatic cancer(PDAC) and prostate cancer(PCa).
In Phase II, participants with selected advanced solid tumors - including locally advanced or metastatic non-small cell lung cancers (AGA [actionable genomic alterations] negative NSCLC, Cohort 1; EGFR-mutant NSCLC, Cohort 2; NSCLC with actionable driver alterations other than EGFR-sensitive mutations, Cohort 3; colorectal cancer (CRC), Cohort 4; squamous cell carcinoma of head and neck (HNSCC), Cohort 5; urothelial carcinoma (UC), Cohort 6; cervical cancer (CC), Cohort 7; esophageal squamous cell carcinoma (ESCC), Cohort 8 - will be enrolled to further assess the efficacy, safety, tolerability, pharmacokinetics of CS5006 at the tentative RP2D(s).
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 2
- Fase 1
Contatti e Sedi
Contatto studio
- Nome: Crystal Wang
- Numero di telefono: +86-021-60332455
- Email: wangjingru@cstonepharma.com
Luoghi di studio
-
-
New South Wales
-
North Ryde, New South Wales, Australia, 2109
- Macquarie University
-
Investigatore principale:
- John Park, Dr
-
Randwick, New South Wales, Australia, 2031
- Scientia Clinical Research Ltd
-
Investigatore principale:
- Charlotte lemech, Dr
-
-
Victoria
-
Clayton, Victoria, Australia, 3168
- Monash Medical Centre
-
Investigatore principale:
- Sophia Frentzas, Dr
-
-
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Cina, 200123
- Shanghai East Hospital
-
Investigatore principale:
- Caicun Zhou
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Evidence of a personally signed and dated informed consent document.
- Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
- Being ≥ 18 years of age on the day of signing informed consent.
- Pathologically or cytologically confirmed, unresectable advanced solid tumors.
- Participants must have at least one measurable lesion according to RECIST Version1.1.
- Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 or 1.
- Adequate organ function.
- Life expectancy ≥ 3 months.
- Fertile men and women of childbearing potential must agree to use an effective method of birth control from providing signed consent and for 180 days after the last study drug administration
Exclusion Criteria:
- Has disease that is suitable for local treatment administered with curative intent.
- Has a history of a second malignancy active within the previous 3 years except for locally curable cancers that have been apparently cured.
- Known primary central nervous system (CNS) tumor or solid tumor CNS metastasis that is symptomatic, untreated, or requires therapy.
- Has life-threatening bleeding event or severe bleeding within 3 months prior to first dose.
- Has uncontrolled pleural effusion, pericardial effusion, or ascites.
- Has immune deficient disease or received systemic immunosuppressive treatment.
- Has intestinal obstruction,or history of inflammatory bowel disease,or chronic diarrhea.
- Has history of (non-infectious) interstitial lung disease/pneumonitis that required steroids.
- Has active infections requiring systemic therapy.
- Has significant cardiovascular disease or cerebrovascular accident within specified timeframes prior to first dose.
- Insufficient washout from prior anti-tumor therapy.
- Received live vaccine within 28 days prior to first dose.
- History of allogeneic organ or hematopoietic stem cell transplantation.
- History of hypersensitivity to excipients of study drug or any monoclonal antibody.
- Any toxic effects of prior therapy unresolved to Grade ≤1.
- Pregnant or breastfeeding women.
- Other acute or chronic medical or psychiatric conditions that may increase risk or interfere with study results, in the investigator's judgment.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Dose Escalation
Participants will be administered escalating doses of CS5006. |
CS5006 will be administered via intravenous (IV) infusion on Day 1 of repeated 21-day cycles (Q3W). |
|
Sperimentale: Dose Expansion
Participants will be administered the recommended dose(s) of CS5006 according to dose-escalation data. |
CS5006 will be administered via intravenous (IV) infusion on Day 1 of repeated 21-day cycles (Q3W). |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
[Espansione della dose] Tasso di risposta obiettiva (ORR) valutato dagli sperimentatori secondo RECIST v1.1
Lasso di tempo: Fino a circa 2 anni
|
Fino a circa 2 anni
|
|
|
[Dose Escalation] The incidence and severity of adverse events (AEs)
Lasso di tempo: Up to approximately 2 years
|
Up to approximately 2 years
|
|
|
[Dose Escalation] Maximum tolerated dose (MTD) of CS5006
Lasso di tempo: Cycle 1 (Up to 21 Days)
|
Participants will receive CS5006 via intravenous (IV) infusion on Day 1 of repeated 21-day cycles (Q3W). The MTD will be determined, if any, by the number of participants who experience a dose limiting toxicity (DLT). |
Cycle 1 (Up to 21 Days)
|
|
[Dose Escalation] Tentative recommended Phase II dose (RP2D) of CS5006
Lasso di tempo: Up to approximately 2 years
|
The selection of tentative RP2D will be based on consideration of overall safety information together with available pharmacokinetic, pharmacodynamic, and efficacy data. The tentative RP2D may be the MTD or a lower dose within the tolerable dose range. |
Up to approximately 2 years
|
Misure di risultato secondarie
Misura del risultato |
Lasso di tempo |
|---|---|
|
[Aumentare la dose] Tasso di risposta obiettiva (ORR) valutato dagli sperimentatori secondo RECIST v1.1
Lasso di tempo: Fino a circa 2 anni
|
Fino a circa 2 anni
|
|
[Dose Escalation & Expansion] Area under the curve (AUC) of CS5007
Lasso di tempo: Up to approximately 2 years
|
Up to approximately 2 years
|
|
[Dose Escalation & Expansion] Duration of response (DOR) evaluated by investigators per RECIST v1.1
Lasso di tempo: Up to approximately 2 years
|
Up to approximately 2 years
|
|
[Dose Escalation & Expansion] Disease control rate (DCR) evaluated by investigators per RECIST v1.1
Lasso di tempo: Up to approximately 2 years
|
Up to approximately 2 years
|
|
[Dose Expansion] The incidence and severity of adverse events (AEs)
Lasso di tempo: Up to approximately 2 years
|
Up to approximately 2 years
|
|
[Dose Escalation & Expansion] Maximum concentration (Cmax) of CS5006
Lasso di tempo: Up to approximately 2 years
|
Up to approximately 2 years
|
|
[Dose Escalation & Expansion] Time to maximum concentration (Tmax) of CS5006
Lasso di tempo: Up to approximately 2 years
|
Up to approximately 2 years
|
|
[Dose Escalation & Expansion] Elimination half-life (t1/2) of CS5006
Lasso di tempo: Up to approximately 2 years
|
Up to approximately 2 years
|
|
[Dose Escalation & Expansion] Clearance (CL) of CS5006
Lasso di tempo: Up to approximately 2 years
|
Up to approximately 2 years
|
|
[Dose Escalation & Expansion] Volume of distribution (Vz) of CS5006
Lasso di tempo: Up to approximately 2 years
|
Up to approximately 2 years
|
|
[Dose Escalation & Expansion] Trough concentration (Ctrough) of CS5006
Lasso di tempo: Up to approximately 2 years
|
Up to approximately 2 years
|
|
[Dose Escalation & Expansion] Accumulation ratio (R) of CS5006
Lasso di tempo: Up to approximately 2 years
|
Up to approximately 2 years
|
|
[Dose Escalation & Expansion] Number of participants with anti-CS5006 antibodies
Lasso di tempo: Up to approximately 2 years
|
Up to approximately 2 years
|
Collaboratori e investigatori
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Altri numeri di identificazione dello studio
- CS5006-101
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .